Background: Post-transplant non-melanoma skin cancers (NMSC) are the most common malignancies in kidney transplant recipients. Objectives: To analyse risk factors associated with the occurrence of basal cell carcinomas (BBC) and squamous cell carcinomas (SCC) in kidney transplant recipients. Materials and methods: Statistical analysis was performed on 376 kidney transplant recipients screened for NMSC in 2002-2009 and followed until 2013. Results: NMSC developed in 23.67% of individuals with an SCC/BCC ratio of 2.15:1 and an agestandardised incidence ratio (IR) of 2.71 cases (95% CI: 1.97-3.46) per 100 patients/year. Based on multivariable analysis, NMSC occurrence significantly correlated with higher age (p<0.001), fair skin type (p = 0.01), and particularly SCCs with male gender (p = 0.001). Patients with >10 actinic keratoses were at higher risk of developing NMSCs (IRR = 2.95; 95% CI: 1.97-4.42; p<0.001) and more prone to SCCs, compared to BCCs (p = 0.04). Also, more SCC carriers had high counts of warty lesions (p = 0.006). Calcineurin inhibitors were associated with higher NMSC incidence (IRR = 2.81; 95% CI: 1.1-7.01; p = 0.03), while no difference was seen with the mammalian target of rapamycin (mTOR) inhibitors. Conclusion: Our results confirm an influence of the individual immunosuppressive regimen, in addition to the duration of immunosuppression, and suggest that older patients, males, fair skinned recipients or those affected with high counts of actinic keratoses (field cancerisation) are particularly prone to development of NMSC.
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Key words: immunosuppression, kidney transplant recipients, nonmelanoma skin cancer N on-melanoma skin cancer (NMSC) is the most common type of neoplasm in humans and also the malignant disease that is increasingly prevalent among organ transplant recipients (OTRs) due to longterm immunosuppressive therapy and other factors [1] . Tumours can be more aggressive in OTRs than in the general population with a rapid progression and destructive behaviour, resulting in significantly higher morbidity and mortality [2] . In contrast to the immunocompetent population, skin cancers in OTRs are dominated by squamous cell carcinoma (SCC), followed by basal cell carcinoma (BCC). In fact, transplanted individuals of Caucasian origin have a 60-to 250-fold increased risk of SCC and a 10-fold increased risk of BCC, but an apparent incidence of malignant melanoma of only 2-3 fold higher than that in the general population [3, 4] . SSCs develop predominantly in areas of field cancerisation with multiple actinic keratoses (AK) or Bowen disease and their risk of metastases is increased to approximately 8% for OTRs, compared to 0.5-5% in the general population [5] . Moreover, SCCs and BCCs occur earlier in OTRs compared to immunocompetent controls, and their cumulative incidence appears to rise linearly without a delay after transplantation, with a decreasing time interval for subsequent tumours [6] . As well as immunosuppression, other potential co-factors contributing to a higher risk of NMSCs in this patient group should be considered. Among the better defined co-stimuli, indicative of an increased NMSC risk in OTRs patients, are ultraviolet radiation exposure, male sex, fair skin, presence of keratotic skin lesions, age at transplantation, or duration and extent of the immunosuppression therapy [7, 8] . In addition, the choice of immunosuppressive agents may be relevant regarding an augmented risk in these patients [9] . Following an initial report based on a previous multivariable analysis of 243 renal transplant patients, observed by our group until 2005 [10] , we set out to extend this study and further validate the parameters that determine the occurrence of SCCs and BCCs based on a retrospective cohort of 376 kidney transplant recipients, with an aim to better define the potential impact of immunosuppressive drugs administered to these patients.
Materials and methods

Patient cohort
Data from 376 patients who underwent renal transplantation between May 1970 and January 2009 were retrospectively collected and follow-up examinations were reported up to the end of 2013. Starting as of 2002, all patients were examined at our special dermatological consultation unit at the department of nephrology in accordance with internal guidelines of the University of Bern and screened for the occurrence of new NMSC and respective premalignant lesions. The study was approved by the local ethical committee and all patients gave written informed consent. Prior to kidney transplantation, all patients had been checked by a dermatologist for skin cancers and/or premalignant conditions and treated for evident lesions. Apart from patient-specific characteristics at study entrance (age, sex, skin type, duration of immunosuppression, and type of immunosuppression), the following parameters were documented and followed in addition at each visit: all clinically evident skin lesions with a suspicion of AK, SCC or BCC, as well as the type and dosage of immunosuppression. If a lesion was clinically clearly recognised as AK, treatment was performed without histological confirmation. In all other cases, a punch biopsy was evaluated histologically.
Statistical analysis
For descriptive purposes, data are presented as means and standard deviations (SD) or numbers with percentages for continuous and categorical variables, respectively. Incidence of first NMSC was computed as incidence rate (IR) per 100 patients/year, together with the 95% confidence interval (CI), by assuming a Poisson distribution. Agestandardised IR was calculated by taking the age structure of the 2000 EU population as reference. For graphical purposes, cumulative incidence rates were computed by means of Kaplan-Meier analysis. The Pearson's 2 test was used to test for difference between categorical variables. Multiple Poisson regression analysis, including terms for age and gender, was used to assess which factors influenced the incidence of first NMSC in the first 20 years of immunosuppression. Effects of selected factors were expressed as incidence rate ratios (IRR) along with their 95% CI and p value. Robust standard errors of parameter estimates were computed to control for mild violation of equal mean and variance assumption. This was also tested by considering a ratio of the deviance and the degree of freedom of its distribution lower than 1. A continuity correction was applied to the univariate Poisson model in case of zero entries in one stratum. Analyses were carried out with SPSS version 20 (IBM Corp). All tests were considered significant at p<0.05.
Results
Patient characteristics are summarized in table 1. The mean age of patients at transplantation was 44.1 ± 14.6 years (mean ± SD), with a male:female ratio of 1.63:1. Most had a skin type of I or II (54.0%) according to Fitzpatrick types I-VI. Overall, the number of AK lesions at study entry was between 1-10 for 39.2% of patients and over 10 Figure 1 . NMSC cumulative incidence rates since transplantation, overall (A) and relative to age groups (B).
for 6.9%. The mean immunosuppressive treatment duration was 10.6 ± 7.4 years including all follow-up visits (mean number of consultations: 3.54 ± 3.43). A mean of 2.54 ± 0.6 immunosuppressive drugs were combined in 22 different regimens. Overall, the most prescribed treatments were prednisone (89.3%) and cyclosporine (81.9%), followed by MMF (35.5%) and azathioprine (32.0%). Among our 233 male and 143 female renal transplant recipients, a total of 89 individuals (23.67%) developed at least one NMSC ( figure 1A) . The mean duration until the detection of first skin cancer was 12.56 ± 7.6 years. 
Discussion
Considering the success rates in kidney grafting together with an ongoing demand, we are facing a steadily increasing number of long-term renal transplant survivors. Given the high incidence and aggressive biological behaviour of NMSC in affected recipients, early detection and removal of NMSCs and respective precursor lesions has become a major challenge. The group screened for skin cancer in this study was predominantly composed of male recipients and our data confirmed an increased risk of developing mainly SCCs. This gender difference reflects data frequently reported by other studies with less females being affected by end-stage renal disease, while in some countries, persisting gender discrimination, in terms of benefiting from medical treatment, might explain a more pronounced impact [11] . The association of male gender with a higher incidence of potentially metastatic SCCs makes male Figure 2 . NMSC cumulative incidence rates in the first 20 years after transplantation, relative to use of cyclosporine/tacrolimus (A) and sirolimus/everolimus (B).
kidney recipients an even more sensitive target group for education efforts, regular skin examinations, and preventive measures. Epidemiological studies have demonstrated NMSCs to be the most common malignancies arising after organ transplantation in Caucasians [12] and a recent Swedish population-based investigation confirmed these results, with the bulk of the excess risk driven by an exceptionally high and accelerating risk of SCC [13] . Our current data, with 23.67% of patients developing NMSCs after a mean of 12.56 ± 7.6 years post-transplantation, are in accordance with those reported from other cohort studies. Indeed, the incidence of NMSC in the US-and western European recipient population increases from 10% to 27% at 10 years and from 40% to 60% at 20 years post-transplantation, compared to the highest incidence reported in Australia, which is even 80% at 20 years [5] . In contrast, latest data from Korean and Chinese transplant centres further revealed a dissimilar malignancy pattern in Asian organ recipients. Whereas the risk of several cancer types is higher than that in the general population, even in long-term followups, the cumulative incidence of post-transplantation skin cancer remains extremely low, compared to populations in western countries [14, 15] . Consequently, the burden of NMSCs contributes to a substantial morbidity in OTRs of Caucasian origin. In a retrospective analysis of the Irish Renal Transplant Database of 255 patients with ultra-long-term (>20 year) renal allograft survival, skin cancer was by far the leading comorbidity (36.1%), followed by coronary heart disease (17.3%) and other malignancies (14.5%) [16] . Accordingly, NMSCs add to a substantial economic load of health care costs for renal graft recipients and may even be responsible for post-transplant mortality [17] . At least, in Australian liver and cardiothoracic transplant recipients, de novo cancer was a leading cause of late death, with the highest relative risk associated with NMSC [18] . Thus, apart from screening awareness and a close collaboration between renal transplant teams and dermatologists, photo-protection, skin self-examination, or a change in immunotherapy were suggested as effective measures against NMSC development in such patients [19] . Primarily, a preventive and aggressive treatment of actinic keratosis in areas of field cancerisation is recommended to cut down on the high morbidity and avoid the mortality associated with invasive squamous cell carcinoma in OTRs [2] . Also, a conversion of immunosuppressive drugs to mTOR inhibitors has been demonstrated to reduce the development of new AKs and NMSCs in several studies, as reviewed in a recent meta-analysis of 5,876 subjects from 21 randomised trials [20] . According to Karayannopoulou and co-workers, the considerably higher expression of phospho-mTOR in SCCs compared to BCCs might explain their higher sensitivity to mTOR inhibitors [21] . In our study, among 33 patients (7.95%) receiving sirolimus on first visit, only two subjects developed BCCs while no SCC could be observed. Yet, no difference could be demonstrated when compared to patients without mTOR inhibitors, probably due to a lack of power in our cohort. In summary, our current data suggest older patients, males, fair skinned recipients, and those presenting multiple warty lesions or field cancerisation comprise a particularly highrisk group for NMSCs among renal transplant recipients who should probably benefit best from close follow-up and active surveillance.
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